Jump to content


Radotinib in the treatment of chronic phase chronic myeloid leukemia patients

  • Please log in to reply
4 replies to this topic

#1 gerry


    Advanced Member

  • Members
  • PipPipPip
  • 1,035 posts

Posted 09 January 2015 - 01:55 AM


#2 rcase13


    Advanced Member

  • Members
  • PipPipPip
  • 523 posts
  • LocationCharlotte, NC

Posted 09 January 2015 - 07:21 AM

This is the first I have heard of Radotinib. Too bad the article wasn't written in southern English! I understood about half of it! They need to have a dumbed down translation for southerns like me!

10/01/2014 100% Diagnosis (WBC 278k, Blasts 6%, Spleen extended 20cm)

01/02/2015 0.06% Tasigna 600mg
04/08/2015 0.01% Tasigna 600mg
07/01/2015 0.01% Tasigna 600mg
10/05/2015 0.02% Tasigna 600mg
01/04/2016 0.01% Tasigna 600mg
04/04/2016 PCRU Tasigna 600mg
07/18/2016 PCRU Tasigna 600mg
10/12/2016 PCRU Tasigna 600mg
01/09/2017 PCRU Tasigna 600mg
04/12/2017 PCRU Tasigna 600mg
10/16/2017 PCRU Tasigna 600mg
01/15/2018 PCRU Tasigna 600mg


Cancer Sucks!

#3 Trey


    Advanced Member

  • PS Beta Group
  • PipPipPip
  • 1,705 posts
  • LocationSan Antonio, Texas

Posted 09 January 2015 - 11:22 AM

Still early in clinical trials.  Results are good but a rather high rate of drug interruptions and patients quitting the drug before 12 months:

71.4% of the patients had a dose interruption

42.9% of the patients discontinued treatment before 12 months


But more drug options is always good.  Maybe it will have a niche role.  Approval may be a couple years away.  This drug is being developed by a Korean company, so it may be available in Asia earlier.

#4 gerry


    Advanced Member

  • Members
  • PipPipPip
  • 1,035 posts

Posted 08 February 2016 - 06:04 PM

In CML: Radotinib as Frontline Therapy; Ponatinib Promising for T315I Patients


ORLANDO, Florida—Two tyrosine kinase inhibitors (TKIs)—one a new drug from Korea, the other designed to target hard-to-treat T315I mutations—show promise as potential treatments for chronic myeloid leukemia (CML) to replace imatinib or allogeneic stem cell transplant (SCT) in selected patients, according to two new studies presented here at the American Society of Hematology Annual Meeting.


#5 survenant


    Advanced Member

  • Members
  • PipPipPip
  • 98 posts

Posted 10 February 2016 - 02:55 PM

See also   Supect (Radotinib) 

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users